CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates

Impact · against what's priced in

CorMedix shows positive short-term variance by beating consensus estimates for both revenue and EPS. However, the fundamental trend is sharply negative, with revenue falling ~48% year-over-year and earnings swinging from a gain to a loss.

CRMD+0.10

No priced-in read yet

In context

The company beat revenue estimates by 3.89% ($54.52 million) and reported a smaller loss than expected (-$0.04 vs -$0.09 EPS), though this follows a massive year-over-year revenue decline of roughly 48%.

Read from the article alone

• healthcare
• earnings
• pharmaceuticals
• CRMD
• biomedical
• earnings surprise
• genetics
• medical devices
• revenue beat

Search tags